Mechanism of action of rituximab

  title={Mechanism of action of rituximab},
  author={Thomas Cerny and Bettina Borisch and Martino Introna and Peter W M Johnson and Andrea L. Rose},
  journal={Anti-Cancer Drugs},
&NA; Rituximab, the humanized chimeric anti‐CD20 monoclonal antibody, represents a powerful tool for treating B‐cell malignancies and is licensed for the treatment of relapsed or chemorefractory low‐grade or follicular non‐Hodgkin's lymphoma (NHL). It has a unique mode of action and can induce killing of CD20+ cells via multiple mechanisms. The direct effects of rituximab include complement‐mediated cytotoxicity and antibody‐dependent cellmediated cytotoxicity, and the indirect effects include… 
Targeted therapies in rheumatoid arthritis: Focus on rituximab
Rituximab treatment led to significant improvements in disease activity of RA patients and the current review summarizes the results from phase III, randomized clinical trials that have been performed, and data on safety and quality of life are summarized.
Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.
It is found that the expression of membrane complement regulatory proteins (mCRPs), CD55 and CD59 on non-small cell lung cancer (NSCLC) cells was closely correlated with histological types, prognosis and preoperational adjutant chemotherapy of the disease.
Immunotherapy for B-acute Lymphoblastic Leukemia by Focusing on Monoclonal Antibody and CAR- T-cell Application
The results and current status of investigational monoclonal antibody-based therapies in ALL are updated and unconjugated and conjugated antibodies to cytotoxic agents for treatment of B-cell ALL are under investigation.
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.
This reagent provides new insights into the binding of rituximab at the cell surface and demonstrates a mode of binding that could be exploited for the surface detection of other mAbs with clinical and biologic applications.
Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!
Those immunotherapeutic strategies that have arrived as far as clinical trials in human subjects are discussed, including mycophenolate mofetil, an anti-proliferative immunosuppressant which has had good success over the last 10 yrs, with similar early efficacy to cyclophosphamide when used as induction therapy for lupus nephritis.
In vivo effect of Rituximab on regulatory T cells and apoptosis in patients with rheumatoid arthritis
It is suggested that Rituximab seems to exert an interesting effect on regulatory T cells in patients with RA; this phenomenon may contribute to the therapeutic effect of this anti-CD20 agent in RA.
Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies
The therapeutic implications, current status and results of monoclonal antibody-based therapy in adult B-cell ALL are reviewed.
Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
  • A. Rao, K. Schmader
  • Medicine, Biology
    The American journal of geriatric pharmacotherapy
  • 2007